Published in Aging and Elder Health Week, January 23rd, 2005
This low dose study was primarily designed to evaluate safety and provide preliminary efficacy information for the use of the MyoCell and MyoCath technologies in patients with Congestive Heart Failure (CHF). Patients selected to participate in the clinical trials exhibited symptoms on average that were consistent with NYHA Class III heart failure patients. The first patient...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.